

Rec'd PCT TO 01 AUG 2005  
10/544093

PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:  
ROSEMARIE CELLI  
TOWNSEND AND TOWNSEND AND CREW LLP  
TWO EMBARCADERO CENTER  
8TH FLOOR  
SAN FRANCISCO, CA 94111-3834

PCT

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing (day/month/year) <b>14 DEC 2004</b>	
Applicant's or agent's file reference <b>15270J-98-IP</b>	
FOR FURTHER ACTION See paragraph 2 below	
International application No. <b>PCT/US04/02856</b>	International filing date (day/month/year) <b>31 January 2004 (31.01.2004)</b>
Priority date (day/month/year) <b>01 February 2003 (01.02.2003)</b>	
International Patent Classification (IPC) or both national classification and IPC <b>IPC(7): C12N 15/85, 15/86; A61K 39/00, 39/395; C07K 5/00 and US Cl.: 530/300,350.387.3; 424/130.1,178.1,184.1; 435/325</b>	
Applicant <b>NEURALAB LIMITED</b>	

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☒ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer Christopher J Nichols, Ph.D. Telephone No. 703-308-0196
--	--

Form PCT/ISA/237 (cover sheet) (January 2004)

BEST AVAILABLE COPY

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/02856

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This opinion has been established on the basis of a translation from the original language into the following language \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

☐ a sequence listing

☐ table(s) related to the sequence listing

b. format of material

☐ in written format

☐ in computer readable form

c. time of filing/furnishing

☐ contained in international application as filed.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority for the purposes of search.

3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/US04/02856

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Claims Please See Continuation Sheet YES

Claims Please See Continuation Sheet NO

Inventive step (IS)

Claims Please See Continuation Sheet YES

Claims Please See Continuation Sheet NO

Industrial applicability (IA)

Claims Please See Continuation Sheet YES

Claims Please See Continuation Sheet NO

2. Citations and explanations:

Claims 1, 4-6, 8, 14, 17, 27, 28, 48, 51-53, 55, 61, 64, 74, 75, 96, and 99-102 lack novelty under PCT Article 33(2) as being anticipated by US 2002/0162129 A1 (LANNEFLT, L. ET AL.) 31 October 2002 (31.10.2002). US 2002/0162129 A1 teaches a method of immunization with Abeta fragments for treatment of Alzheimer's disease, pharmaceutical compositions, polynucleotide vaccines, and immunogenic fragments comprising same.

Claims 1, 4-6, 8, 14, 17, 27, 28, 48, 51-53, 55, 61, 64, 74, 75, 96, and 99-102 lack novelty under PCT Article 33(2) as being anticipated by US 2002/0094335 A1 (CHALIFOUR, R. ET AL.) 18 July 2002 (18.07.2002). US 2002/0094335 A1 teaches a method of immunization with Abeta fragments for treatment of Alzheimer's disease, pharmaceutical compositions, polynucleotide vaccines, and immunogenic fragments comprising same.

Claims 1, 4-6, 8, 48, 51-53, 55, 57-58, 96, and 99-102 lack novelty under PCT Article 33(2) as being anticipated by SCHENK, D. ET AL. Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 8 July 1999, Vol. 400, No. 6740. SCHENK, D. ET AL. teaches a method of immunization with Abeta fragments for treatment of Alzheimer's disease, pharmaceutical compositions, and immunogenic fragments comprising same.

Claims 1, 4-6, 8, 48, 51-53, 55, 57-58, 96, and 99-102 lack novelty under PCT Article 33(2) as being anticipated by SIGURDSSON, E.M. ET AL. Immunization with a Nontoxic/Nonfibrillar Amyloid-b Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice. American Journal of Pathology August 2001, Vol. 159, No. 2, pages 439-447. SIGURDSSON, E.M. ET AL. teaches a method of immunization with Abeta fragments for treatment of Alzheimer's disease, pharmaceutical compositions, and immunogenic fragments comprising same.

Claims 1, 4-6, 8, 48, 51-53, 55, 57-58, 96, and 99-102 lack novelty under PCT Article 33(2) as being anticipated by LEMERE, C.A. ET AL. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiology of Aging November/December 2002, Vol. 23, No. 6. LEMERE, C.A. ET AL. teaches a method of immunization with Abeta fragments for treatment of Alzheimer's disease, pharmaceutical compositions, and immunogenic fragments comprising same.

Claims 1, 4-6, 8, 14, 17, 27, 28, 48, 51-53, 55, 61, 64, 74, 75, 96, and 99-102 lack an inventive step under PCT Article 33(3) because inventions lacking novelty do not have an inventive step.

Claims 1, 4-6, 8, 14, 17, 27, 28, 48, 51-53, 55, 61, 64, 74, 75, 96, and 99-102 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/US04/02856

**Box No. VII Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:

Claim 48 is objected to under PCT Rule 66.2(a)(iii) as containing the following defect(s) in the form or contents thereof: typo in the fifth line.

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/US04/02856

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

V.1. Reasoned Statements:

The opinion as to Novelty was positive (Yes) with respect to claims 2-3, 7, 9-13, 15-16, 18-26, 29-47, 49-50, 54, 56-60, 62-63, 65-73, 76-95, 97-98

The opinion as to Novelty was negative (No) with respect to claims 1, 4-6, 8, 14, 17, 27, 28, 48, 51-53, 55, 61, 64, 74, 75, 96, 99-102

The opinion as to Inventive Step was positive (Yes) with respect to claims 2-3, 7, 9-13, 15-16, 18-26, 29-47, 49-50, 54, 56-60, 62-63, 65-73, 76-95, 97-98

The opinion as to Inventive Step was negative(NO) with respect to claims 1, 4-6, 8, 14, 17, 27, 28, 48, 51-53, 55, 61, 64, 74, 75, 96, 99-102

The opinion as to Industrial Applicability was positive (YES) with respect to claims 1-102

The opinion as to Industrial Applicability was negative(NO) with respect to claims NONE

## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the *PCT Applicant's Guide*, a publication of WIPO.

In these Notes, "Article," "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended ?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Preliminary Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

**When ?** Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments ?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

**How ?** Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

#### What documents must/may accompany the amendments ?

##### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

#### NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

#### "Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

#### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

#### Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the *PCT Applicant's Guide*, Volume II.